“Patent Expirations Will Stabilize the Pharmaceutical Industry.”
I must believe it, because I’m quoted in the St. Louis Observer as having said it!
The reporter did a good job of capturing what I meant, quoting me as saying “the industry will be more diverse, with a more stable, though smaller, revenue base spread among many more products.”
To expand, I think that the loss of patents on some of the larger brands will mean that the pharmaceutical industry will rely on a larger number of smaller-market products for the lion’s share of its revenues. The loss of marketing exclusivity on drugs like Lipitor, Nexium, and Plavix will mean that drug companies will need to derive their revenues from a greater number of products. While this might be bad for Pfizer, Astrazeneca, and Sanofi Aventis, the overall result should be a healthier, less volatile, pharmaceutical industry.